en · de · es · pt
tb-500-notes.peptides6088.com › Wiki › Identity And Research Background — Research Overview

Identity And Research Background — Research Overview

By Editorial Desk · published 2025-10-17 · last reviewed 2025-11-17 · Wiki

Everything below concerns actin-binding fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-17. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity and Research Background

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Handling, Storage, and Analytical Verification

Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.

Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Acetylated heptapeptide form
Monoisotopic mass888.5 DaAverage mass about 889 Da
AppearanceWhite to off-white solidUsually supplied as lyophilised powder
Solubility classHighly water solubleAlso dissolves in aqueous buffers
Common synonymsTbeta4 fragment, thymosin beta-4 (17-23)Refer to the same sequence

Identity and Reported Background

Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.

TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.

Related pages on this site

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Reference notes

=== Epilepsy === In the United States, the Food and Drug Administration (FDA) has indicated only one brand of prescription cannabidiol, sold under the brand name Epidiolex, for the treatment of seizures associated with Dravet syndrome, Lennox–Gastaut syndrome, or tuberous sclerosis complex in people one year of age and older. While Epidiolex treatment is generally well tolerated, it is associated with minor adverse effects, such as gastrointestinal upset, decreased appetite, lethargy, sleepiness, and poor sleep quality. In the European Union, Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox–Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, for people aged two years of age and older. In 2020, the label for Epidiolex in the US was expanded to include seizures associated with tuberous sclerosis complex. Epidiolex/Epidyolex is the first prescription formulation of plant-derived cannabidiol approved by regulatory bodies in the US and Europe.

Barnsley Football Club is a professional football club in Barnsley, South Yorkshire, England. The club competes in EFL League One, the third tier of English football. Nicknamed “the Reds”, "the Tykes" or less commonly "the Colliers", they were founded in 1887 by Reverend Tiverton Preedy and moved to Oakwell the following year. The club's original blue colours were changed to red and white in 1904. Barnsley spent the 1890s in the Sheffield & District, Midland and Yorkshire leagues, before gaining admittance to the Football League Second Division in 1898. They twice reached the final of the FA Cup whilst still in the second tier, losing to Newcastle United in 1910 and winning the competition over West Bromwich Albion in 1912. The club suffered relegation in 1933, but secured promotion as Third Division North champions in 1934. They won the Third Division North title for a second time in 1939, having been relegated the previous season. Relegated again in 1953, they secured another Third Division North title in 1955. However, further relegations left them in the fourth tier of English football by 1966. Promotion from the Fourth Division was achieved in 1968, though they were relegated after just four seasons. The club secured two promotions in three years under the stewardship of Allan Clarke and Norman Hunter, and from 1981 would spend sixteen consecutive years in the second tier. Premier League football was secured for the 1997–98 season with a second-place finish in the First Division, though they were relegated after one season and dropped down to the third tier in 2002.

Mint tea is a herbal tea made by infusing mint leaves in hot water. Mint tea can be brewed with fresh leaves, or with dehydrated leaves that have been dried to a moisture level of less than 10%. Mint tea made with peppermint leaves is called peppermint tea, and mint tea made with spearmint is called spearmint tea. There also exist teas that infuse peppermint and spearmint leaves. In Korea, traditional mint tea called bakha-cha (박하차) is made with East Asian wild mint leaves. In India, traditional mint tea called pudina chai (पुदीना चाय) is made by steeping spearmint or peppermint in hot chai. Due to the high content of essential oils in leaves (1–2.5%), especially menthol, mint tea is popular for its curative effects. Affecting the digestive system and excretion of gastric juices, it is thought to act as an anti-inflammatory.

== Biosynthesis == NAAG synthetase activity mediates the biosynthesis of NAAG from glutamate and NAA, but little is known about the mechanism or regulation of this enzyme, and no NAAG synthetase activity has been isolated in cell-free preparations. Since other neuropeptides and nearly all vertebrate peptides are synthesized by post-translational processing, NAAG synthetase activity is relatively unique. As with NAA, the synthesis of NAAG is primarily restricted to neurons, although glial cells also contain and synthesize this peptide. In vitro, NAAG synthesis appears to be regulated by the availability of its precursor, NAA. In addition, during differentiation of neuroblastoma cells, it has been shown that a protein kinase A (PKA) activator will increase the quantity of NAAG, while a protein kinase C (PKC) activator will decrease its concentration. This finding suggests that PKA and PKC have opposing regulatory effects on the NAAG synthetase enzyme.

Sources: en.wikipedia.org

Notes from published material

Aura is a 5–60 minute neurological event that generally occurs just before the onset of the headache. Symptoms can be visual, sensory, or motor in nature. Visual effects occur most frequently, in as many as 99% of cases involving aura. In rare cases known as persistent aura, aura symptoms may remain after 60 minutes. Visual disturbances often consist of a scintillating scotoma or flickering in someone's field of vision that may interfere with their ability to read or drive. This typically starts near the center of vision and then spreads out to the sides with jagged or zigzagging lines. Lines are usually black and white, but may also appear colored. Some people lose part of their field of vision, while others experience blurring. Sensory auras are the second most common type of aura; they occur in 30–40% of people with auras. A feeling of pins-and-needles may begin on one side in the hand and arm and spread to the nose and mouth area on the same side. Numbness usually occurs after the tingling has passed, with a loss of position sense. Other symptoms of the aura phase can include speech or language disturbances, world spinning, and, less commonly, motor problems. Motor symptoms indicate a hemiplegic migraine, and weakness often lasts longer than one hour unlike other auras.

==== Dance/movement therapy ==== Dance and movement therapy, as a form of active imagination, was developed by Jung and Toni Wolff in 1916 and practiced by Tina Keller-Jenny and other analysts. It remained largely unknown until the 1950s when it was rediscovered by Marian Chace and therapist Mary Whitehouse. Whitehouse, after studying with Martha Graham and Mary Wigman, became a dancer and teacher of modern dance, and, along with Swiss dancer Trudi Schoop, is considered one of the founders of dance/movement therapy in the U.S.

The three substrates of this enzyme are glycine betaine aldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are trimethylglycine, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is betaine-aldehyde:NAD+ oxidoreductase. Other names in common use include betaine aldehyde oxidase, BADH, betaine aldehyde dehydrogenase, and BetB. This enzyme participates in glycine, serine and threonine metabolism.

Sources: en.wikipedia.org

Background from the literature

=== Generic names === Bicalutamide is the generic name of the drug in English and French and its INNTooltip INN, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, AANTooltip Australian Approved Name, and JANTooltip Japanese Accepted Name. It is also referred to as bicalutamidum in Latin, bicalutamida in Spanish and Portuguese, bicalutamid in German, and bikalutamid in Russian and other Slavic languages. The "bica-" prefix corresponds to the fact that bicalutamide is a bicyclic compound, while the "-lutamide" suffix is the standard suffix for NSAAs. Bicalutamide is also known by its former developmental code name ICI-176,334.

==== Drug trafficking and transnational criminal organizations ==== Some jurisdictions whose resident individuals or entities are frequently targeted for sanctions under anti-drug trafficking or transnational criminal organizations-related authorities include:

== Viscosity of oat β-glucan == In oats, β-glucan makes up the majority of the soluble fibre; however, oat β-glucans do become insoluble above a certain concentration. The total viscosity is determined by the level of solubility, the molecular weight, and the trimer-to-tetramer ratio. The lower the trimer-tetramer ratio, the higher the β-glucan viscosity in solution. A more viscous internal β-glucan solution generally leads to beneficial physiological effects – including a more pronounced hypoglycemic effect and lowered cholesterol levels, and a decrease in postprandial blood glucose levels.

== Packaging == Frozen food packaging must maintain its integrity throughout filling, sealing, freezing, storage, transportation, thawing, and often cooking. As many frozen foods are cooked in a microwave oven, manufacturers have developed packaging that can go directly from freezer to the microwave. In 1974, the first differential heating container (DHC) was sold to the public. A DHC is a sleeve of metal designed to allow frozen foods to receive the correct amount of heat. Various sized apertures were positioned around the sleeve. The consumer would put the frozen dinner into the sleeve according to what needed the most heat. This ensured proper cooking. Today there are multiple options for packaging frozen foods. Boxes, cartons, bags, pouches, boil-in-bags, lidded trays and pans, crystallized PET trays, and composite and plastic cans. Scientists continue to research new aspects of frozen food packaging. Active packaging offers many new technologies that can actively sense and then neutralize the presence of bacteria or other harmful species. Active packaging can extend shelf-life, maintain product safety, and help preserve the food over a longer period of time. Several functions of active packaging are being researched:

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

What amino acids make up this peptide?

It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.

How much human data exists for this sequence?

Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.

Can the powder be stored at room temperature?

Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.

Network